News

Avant Institute In Partnership With Cognivue Awarded Grant to Launch Innovative Early Detection Program For Alzheimer’s In Pharmacies Nationwide

Avant Institute is One of Twelve Select Recipients of the Inaugural Global Davos Alzheimer’s Collaborative Grant Program for Healthcare System Preparedness CHARLOTTE, NC (JUNE 8, 2022) – Avant Institute, in partnership with…

Cognivue Recruits Top Scientists for Clinical Advisory Board

ROCHESTER, NY, March 22, 2022 – Neuroscience company Cognivue, Inc. has recruited eight highly respected professionals in the fields of neuroscience, geriatric medicine, psychiatry, and medicine for its new clinical advisory board….

Cognivue and American Institute of Balance Partner to Expand Cognitive Screening

ROCHESTER, N.Y., January 10, 2022—Neuroscience company Cognivue, Inc. has partnered with American Institute of Balance (AIB) to make its cognitive screening products and services available to the AIB provider network of certified…

New Paper Explores Connection Between Vision and Cognitive Function

Dr. Solomon Gould Chronicles His Work with the Cognivue Thrive Screening Device ROCHESTER, N.Y., December 7, 2021—Neuroscience company Cognivue, Inc. has partnered with St. Paul, Minnesota optometrist Solomon Gould, OD on a…

Cognitive Vision Testing in Optometry: Precision “Medicine” for Eye Care

Cognitive Vision Testing in Optometry: Precision “Medicine” for Eye Care By Solomon Gould, OD, MBA Inspired and Supported by Fred Ma, MD, Ph.D., Heather Harris, Mike Pier, OD, Brad Oatney, OD, and…

Cognivue Welcomes Karen Parkyn-Michael as Vice President of Marketing and Strategy

Executive Brings More than 25 Years of Strategic and Commercial Experience in Multinational and Emerging Medical Device Companies ROCHESTER, N.Y., December 2, 2021—Neuroscience company Cognivue, Inc. has named Karen Parkyn-Michael as vice…

Cognivue Launches Real-World Data Collection Project to Study Hearing and Cognitive Function Relationship

12 U.S. Audiology Clinics Participating with the Cognivue ThriveTM Screening Device ROCHESTER, NY, November 16, 2021—Neuroscience company Cognivue, Inc. has launched a nationwide real-world data collection project aimed at confirming a direct…

Cognivue is proud to support Davos Alzheimer’s Collaborative and their global efforts to fight Alzheimer’s Disease

Geneva, 21 September 2021 – The Davos Alzheimer’s Collaborative (DAC) is a global multi-stakeholder partnership that is mobilizing the world against Alzheimer’s disease. DAC announced today it has successfully completed financing of its foundational phase and has launched…

Cognivue, Inc. Initiates Nationwide Clinical Study to Assess Post-COVID-19 Syndrome (Long Haul Syndrome)

ROCHESTER, N.Y., July 8, 2021—Neuroscience company Cognivue, Inc. today announced the initiation of COG-COVID19, an open-label, prospective, two-armed comparison clinical study to assess the impact of COVID-19 on cognitive function. Researchers from…

Cognivue is as Effective as MoCA While Demonstrating Better Test-Retest Reliability for Assessing Cognitive Impairment, According to New Paper

Study Published in Neurological Sciences and Neurosurgery Shows FDA-Cleared Technology as Having Superior Test-Retest Reliability; Affirms Use as Efficient, Easy-to-Use Alternative to Traditional Pencil-and-Paper Assessment Methods ROCHESTER, N.Y., June 25, 2021—Neuroscience company…

Avant Institute In Partnership With Cognivue Awarded Grant to Launch Innovative Early Detection Program For Alzheimer’s In Pharmacies Nationwide

Avant Institute is One of Twelve Select Recipients of the Inaugural Global Davos Alzheimer’s Collaborative Grant Program for Healthcare System Preparedness CHARLOTTE, NC (JUNE 8, 2022) – Avant Institute, in partnership with…

Cognivue Recruits Top Scientists for Clinical Advisory Board

ROCHESTER, NY, March 22, 2022 – Neuroscience company Cognivue, Inc. has recruited eight highly respected professionals in the fields of neuroscience, geriatric medicine, psychiatry, and medicine for its new clinical advisory board….

Cognivue and American Institute of Balance Partner to Expand Cognitive Screening

ROCHESTER, N.Y., January 10, 2022—Neuroscience company Cognivue, Inc. has partnered with American Institute of Balance (AIB) to make its cognitive screening products and services available to the AIB provider network of certified…

New Paper Explores Connection Between Vision and Cognitive Function

Dr. Solomon Gould Chronicles His Work with the Cognivue Thrive Screening Device ROCHESTER, N.Y., December 7, 2021—Neuroscience company Cognivue, Inc. has partnered with St. Paul, Minnesota optometrist Solomon Gould, OD on a…

Cognitive Vision Testing in Optometry: Precision “Medicine” for Eye Care

Cognitive Vision Testing in Optometry: Precision “Medicine” for Eye Care By Solomon Gould, OD, MBA Inspired and Supported by Fred Ma, MD, Ph.D., Heather Harris, Mike Pier, OD, Brad Oatney, OD, and…

Cognivue Welcomes Karen Parkyn-Michael as Vice President of Marketing and Strategy

Executive Brings More than 25 Years of Strategic and Commercial Experience in Multinational and Emerging Medical Device Companies ROCHESTER, N.Y., December 2, 2021—Neuroscience company Cognivue, Inc. has named Karen Parkyn-Michael as vice…

Cognivue Launches Real-World Data Collection Project to Study Hearing and Cognitive Function Relationship

12 U.S. Audiology Clinics Participating with the Cognivue ThriveTM Screening Device ROCHESTER, NY, November 16, 2021—Neuroscience company Cognivue, Inc. has launched a nationwide real-world data collection project aimed at confirming a direct…

Cognivue is proud to support Davos Alzheimer’s Collaborative and their global efforts to fight Alzheimer’s Disease

Geneva, 21 September 2021 – The Davos Alzheimer’s Collaborative (DAC) is a global multi-stakeholder partnership that is mobilizing the world against Alzheimer’s disease. DAC announced today it has successfully completed financing of its foundational phase and has launched…

Cognivue, Inc. Initiates Nationwide Clinical Study to Assess Post-COVID-19 Syndrome (Long Haul Syndrome)

ROCHESTER, N.Y., July 8, 2021—Neuroscience company Cognivue, Inc. today announced the initiation of COG-COVID19, an open-label, prospective, two-armed comparison clinical study to assess the impact of COVID-19 on cognitive function. Researchers from…

Cognivue is as Effective as MoCA While Demonstrating Better Test-Retest Reliability for Assessing Cognitive Impairment, According to New Paper

Study Published in Neurological Sciences and Neurosurgery Shows FDA-Cleared Technology as Having Superior Test-Retest Reliability; Affirms Use as Efficient, Easy-to-Use Alternative to Traditional Pencil-and-Paper Assessment Methods ROCHESTER, N.Y., June 25, 2021—Neuroscience company…